{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:40:50Z","timestamp":1777531250264,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clml.2019.09.616","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T12:51:48Z","timestamp":1569847908000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience"],"prefix":"10.1016","volume":"20","author":[{"given":"Marta","family":"Sobas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Armatys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Ho\u0142owiecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Pluta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Zarzycka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Pi\u0105tkowska-Jakubas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6064-296X","authenticated-orcid":false,"given":"Maciej","family":"Majcherek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Go\u0142os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Paluszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Podhorecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Oleksiuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Skr\u0119t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Hawrylecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Ewa","family":"Guzicka-Kazimierczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzena","family":"W\u0105tek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Gromek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Charli\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Holojda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Mi\u015bkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Martinez-Cuadr\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.09.616_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/j.seminoncol.2008.04.010","article-title":"Acute promyelocytic leukemia: recent advances in diagnosis and management","volume":"35","author":"Lo-Coco","year":"2008","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2019.09.616_bib2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib3","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","article-title":"A\u00a0randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group","volume":"14","author":"Fenaux","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib5","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/blood-2010-01-266007","article-title":"Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome","volume":"115","author":"Sanz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib6","first-page":"1014","volume":"90","author":"Mandelli","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib7","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2009.183","article-title":"High dose Ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG","volume":"23","author":"Lengfelder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.616_bib8","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","article-title":"All-trans-retinoic acid in acute promyelocytic leukemia","volume":"337","author":"Tallman","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.616_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V72.2.567.567","article-title":"Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia","volume":"72","author":"Huang","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib10","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","article-title":"Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia","volume":"107","author":"Estey","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.616_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non\u2013high-risk acute promyelocytic leukemia: final results of the randomized Italian\u2013German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.616_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3324\/haematol.2009.017962","article-title":"Early hemorrhagic death before starting therapy in acute promyelocytoc leukemia: association with high WBC count, late diagnosis and delayed treatment initiation","volume":"95","author":"Breccia","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.09.616_bib14","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0049-3848(10)70013-X","article-title":"Open issues on bleeding and thrombosis in acute promyelocytic leukemia","volume":"125","author":"Sanz","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2019.09.616_bib15","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood.V75.11.2112.2112","article-title":"Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients","volume":"75","author":"Rodeghiero","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2011.78","article-title":"Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry","volume":"25","author":"Lehmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.616_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12931","article-title":"Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study","volume":"166","author":"Paulson","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.09.616_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3324\/haematol.2011.046490","article-title":"Treatment advances have not improved the early death rate in acute promyelocytic leukemia","volume":"97","author":"McClellan","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.09.616_bib19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","article-title":"Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib20","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3324\/haematol.10874","article-title":"Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines","volume":"92","author":"Jacomo","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.09.616_bib21","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2012-08-449918","article-title":"Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking: results of the International Consortium on APL","volume":"121","author":"Rego","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib22","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"de la Serna","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib23","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.616_bib24","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.09.616_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \u201cretinoic acid syndrome\u201d in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2019.09.616_bib26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimations from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2019.09.616_bib28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample test for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.clml.2019.09.616_bib29","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.clml.2019.09.616_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2141.2000.01936.x","article-title":"Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia","volume":"108","author":"Di Bona","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.09.616_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12032-013-0625-5","article-title":"Therapy-related acute promyelocytic leukemia: a systematic review","volume":"30","author":"Rashidi","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2019.09.616_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3324\/haematol.2010.036657","article-title":"Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis","volume":"96","author":"Ammatuna","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.09.616_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00277-016-2622-1","article-title":"Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients","volume":"95","author":"Testa","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.09.616_bib34","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00277-014-2130-0","article-title":"Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells","volume":"93","author":"Breccia","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.09.616_bib35","doi-asserted-by":"crossref","first-page":"421906","DOI":"10.1155\/2014\/421906","article-title":"Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis","volume":"2014","author":"Xu","year":"2014","journal-title":"Dis Markers"},{"key":"10.1016\/j.clml.2019.09.616_bib36","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2010-04-277434","article-title":"Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens","volume":"117","author":"Montesinos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.616_bib37","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1080\/10428194.2018.1516875","article-title":"An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens","volume":"60","author":"Sobas","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:41Z","timestamp":1761870821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019320038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2152265019320038"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.616","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}